Your September Healthtech Radar

01 Funding Radar

Two upcoming deadlines, one always open

Due Thu, Oct 1 · Massachusetts only

MLSC Business Builds: Life Sciences

Between $500K and $2M, up to ten grants, and medtech advanced manufacturing is named explicitly alongside biomanufacturing. Two things to know before you start: it is capital expenses only, and it requires a dollar-for-dollar match that cannot come from another state grant. That makes it a fit for a company already financing a production line, not a pre-revenue team. No LOI stage, so the full application is the first thing you write.

White papers due Fri, Oct 30

MTEC FY2026 Multi-Topic Request for Project Proposals

About $10.5M across fifteen focus areas, funded through a Department of Defense other-transaction vehicle, which moves considerably faster than a standard federal contract. Blast exposure monitoring runs up to $7M per award and musculoskeletal injury sits around $1.5M to $3M. The first stage is a white paper rather than a full proposal, so the cost of taking a swing is low. Check the consortium membership requirement before you start writing.

Rolling · No deadline

ARPA-H Innovative Solution Openings

Four standing openings across Health Science Futures, Proactive Health, Resilient Systems, and Scalable Solutions. These exist for technology that does not fit any advertised ARPA-H program, which describes most interesting device companies. The gate is a short Solution Summary that gets written feedback before you are allowed to submit a full proposal, so it is a cheap way to find out whether a program manager is interested.

02 Stage & Pitch

Applications open right now

Closes Tue, Sept 22 · Eight days out

NNEMTC 2026 Pitch Competition

Five minutes on stage and five minutes of Q&A from investor and operator judges, in front of 300 or so founders, clinicians, and investors at Northeastern's Roux Institute in Portland. The detail Boston readers miss: being based in Northern New England is not a requirement, your application just has to argue why the room fits you. Concept stage through early revenue, with a prototype and some proof of concept preferred. Every application gets read and scored by the panel whether or not you make the finals, which is a reasonable return on the 30 minutes it takes. Finalists pitch in person on November 12 and 13 and have to send a founder or senior leader.

Closes Tue, Sept 29 · Two weeks out

VentureWell E-Team Program

Up to $25K non-dilutive across two stages, plus fully funded training workshops in January. VentureWell is one of the very few funders that will write a check before there is a company, which makes this the right first money for a New England university spinout that has not incorporated. The customer discovery curriculum also maps cleanly onto NSF I-Corps and SBIR readiness.

Closes Thu, Oct 1

CancerX Accelerator, 2027 cohort

The Cancer Moonshot public-private partnership runs this one, and the structure is the interesting part: every startup is matched with at least two champion healthcare organizations. Second and third pilots are the real bottleneck for digital oncology companies, and this is built to solve exactly that. You need a launched or completed pilot already in market to qualify. Program runs February through June 2027.

Opens Wed, Oct 14 · Closes Wed, Oct 28

MIT $100K PITCH

A $5K grand prize and a $2K audience choice award, live competition December 2. Small money, but PITCH is the qualifying door into ACCELERATE in March and the $100K LAUNCH finale in May, and the 90-second format is the right first venue for an idea still half in a lab. At least one currently registered MIT student is required, though outside co-founders, faculty, and alumni are explicitly welcome on the team.

Final deadline Wed, Nov 18 · In Boston

Techstars Boston Accelerator

The only major equity accelerator physically running in Boston with an open deadline right now. Three months of mentor-driven programming starting March 8, demo day June 3, which puts you in front of investors right as the summer seed window opens. Techstars Boston has historically taken health and life-science-adjacent companies. This one takes equity, so read the terms carefully.

03 Upcoming Networking Events

The industry comes to Boston

Tue to Wed, Sept 22 and 23 · Next week

World Medical Innovation Forum: AI in Medicine

Westin Boston Seaport, 425 Summer Street. Mass General Brigham's annual gathering, and last year it pulled roughly 2,000 registrants from 650 organizations. This is the highest concentration of academic medical center leadership, strategics, and healthcare investors Boston sees all year, and where hospital pilots actually get agreed to.

Mon, Sept 28

Fourth Annual MassMEDIC Golf Tournament

Red Tail Golf Club, 15 Bulge Road, Devens. Eighteen-hole scramble, all skill levels, with breakfast, lunch at the turn, and a reception after. Five hours of unstructured time with the suppliers, regulatory consultants, and device executives you would otherwise chase for a 20-minute call. Email [email protected] for a foursome.

Thu, Oct 8 · 1:00 to 5:00 PM

MedTech Ahead Fall Startup Program Kickoff

Beth Israel and the Harvard DCI Network, Boston. An innovation showcase of the fall cohort plus a panel on data quality in medtech, aimed squarely at pre-clinical sensor and algorithm companies. A tight, relevant room rather than a general life sciences crowd. MassMEDIC lists code MASSMEDIC88Q for 30 percent off.

Thu, Oct 15

MassBio 2026 Align Summit

Sheraton Boston, 39 Dalton Street. Fifty-five companies from pre-seed through Series B pitching, plus keynotes and one-on-one partnering meetings. MassBio frames it to include med and healthtech explicitly, not just biotech, so it is a legitimate venue for a device or digital health raise.

Sun to Wed, Oct 18 to 21 · The big one

The MedTech Conference, hosted by AdvaMed

Boston Convention and Exhibition Center. The largest medtech gathering in the country, and this year it is a subway ride away. Startup rates start at $1,100 for AdvaMed members under $1M in revenue and $2,000 for non-members, and standard pricing holds until October 17. Investors, hospital executives, and media go free, which is why the buy side turns out. Pitch applications are closed, but partnering is open.

Mon to Fri, Oct 26 to 30

Tough Tech Week 2026

Distributed across Boston and Cambridge. A full week of panels, pitches, workshops, and expos from The Engine, with Future of Health and Biotech as one of four named tracks. The anchor Tough Tech Summit on October 27 at Hotel Commonwealth is invitation only, but the rest of the week is open and the sessions post to The Engine's calendar. The Blueprint Showcase lands October 29 at 750 Main Street.

04 Featured Company

A multi-sensor wearable patch and edge AI platform for continuous cardiac monitoring at home. The patch measures ECG, heart rate variability, thoracic impedance, respiratory rate, activity, and sleep architecture at once, and runs machine learning on the device itself rather than shipping raw signal to the cloud. The target is heart failure deterioration, caught days before it becomes an admission.

The BraveHeart clinical team published a commentary in the July/August issue of MedNous making the case that chronic disease management has the wrong default. Patients receive care once symptoms become intolerable, by which point the physiological deterioration has already happened. The numbers they marshal are hard to argue with: 6.2 million US adults live with CHF, thirty-day readmission rates run 20 to 25 percent at $10,000 to $20,000 per admission, and five-year mortality sits at 50 percent. Programs using advanced non-invasive wearables have cut readmissions 30 to 50 percent, with the best exceeding 65 percent.

The economic comparison is the part worth sitting with. CardioMEMS, the implantable pulmonary artery sensor, costs $20,000 to $30,000 per patient, requires surgery, and monitors one parameter. A wearable patch costs hundreds of dollars, deploys immediately regardless of surgical candidacy, and measures several parameters continuously. That is not an incremental improvement, it is a change in who can access proactive care at all.

The structural decision other founders should steal is what BraveHeart chose not to do. They are a service enabler, not a service provider. As a Class II device, delivering the monitoring service directly would pull additional FDA obligations onto the company, so instead the clinics and their associated IDTFs deliver it, using service and billing infrastructure that already runs at scale for Holter, extended Holter, and MCT. Go-to-market is small and mid-size cardiac clinics first, an OEM model through large medtech partners as the market matures. Leveraging the existing 510(k) rather than opening a new pathway keeps the regulatory risk narrow, which is exactly what makes a final small-scale study fundable.

“The tools required for transformation are available today. The question is how quickly the field can make it happen.”
Ralph L. Beck, William T. Denman MD, Stephen A. McCalmont, David P. Shimkus, and Warren J. Wexelman MD, writing in MedNous